Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148783 | 0.92 | PTGS2 (0.41) | PTGS2PTGS1CACNA1GCACNA1HTRPV1 | |
| SCHEMBL5151978 | 0.91 | PTGS2 (0.48) | PTGS2PTGS1FABP3FABP4MALT1 | |
| SCHEMBL5147693 | 0.91 | MALT1 (0.41) | PTGS2PTGS1PIK3CAPIK3CGFABP3 | |
| SCHEMBL14504717 | 0.90 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL5148807 | 0.90 | BCL2 (0.42) | PTGS2PTGS1PIK3CAPIK3CGFABP3 | |
| SCHEMBL5148888 | 0.88 | PIK3CA (0.36) | PTGS2PTGS1PIK3CAPIK3CGFABP3 | |
| SCHEMBL5148582 | 0.86 | PTGS2 (0.45) | PTGS2PTGS1FABP3FABP4 | |
| SCHEMBL5152083 | 0.86 | MDM2 (0.39) | PIK3CAPIK3CGFABP3FABP4MALT1 | |
| SCHEMBL6540168 | 0.86 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL5148770 | 0.85 | PTGS2 (0.44) | PTGS2PTGS1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | PTGS2 1780/4885PTGS1 1105/4885CACNA1G 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.